Delivering new products
Without a scalable manufacturing solution, the potential of any ground-breaking scientific discovery can never be translated into real products. This is especially true of new therapeutic modalities, which have historically been slow to deliver on their initial promise. At 4D pharma, we understood the need to develop a repeatable and reliable manufacturing process that gives us an end product that is deliverable to patients.
End to end manufacturing capability
To meet our clinical development targets we have invested in a state-of-the-art, GMP-certified ~1,500 m² manufacturing facility. This gives us an end to end development capability, allowing us to scale our products from glassware in the lab to commercial-scale production. From 5L pilot-scale through to 3000L fermentation we optimise the development of our products in-house, without relying on external manufacturers.
Reproducible and consistent process
The ability to manufacture our products consistently and reproducibly defines our leading position in the microbiome space. Live biotherapeutics are complex products, with the potential to change between batches and over time if not properly controlled. This problem is multiplied exponentially if the product contains multiple organisms. Our single-strain approach allows us to retain exquisite control over the identity, purity, potency and stability of our products. Our in-house development and manufacturing team has more than 15 years’ experience in microbial fermentation.